Session 3: Biology of breast cancer II: Tumor heterogeneity and disease segmentation in breast cancer

Chairs: Fraser W. Symmans (USA), Jonas Bergh (Sweden)

  • Clinical implications of the intrinsic molecular subtypes (Aleix Prat, Spain)
  • Heterogeneity of Triple Negative subtype: Gene expression profile and phenotype (Brian D. Lehmann, USA)
  • Molecular segmentation in Luminal breast cancer: How to select the driver pathways (Sherene Loi, Australia)
  • Insights in biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications (Nadja Harbeck, Germany)
  • Discussion